Citadel Advisors’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $258K | Sell |
195,500
-145,500
| -43% | -$260K | ﹤0.01% | 10823 |
|
|
2025
Q4 | $638K | Buy |
341,000
+107,200
| +46% | +$206K | ﹤0.01% | 8427 |
|
|
2025
Q3 | $299K | Buy |
233,800
+111,600
| +91% | +$151K | ﹤0.01% | 10376 |
|
|
2025
Q2 | $152K | Buy |
122,200
+2,800
| +2% | +$3.23K | ﹤0.01% | 10946 |
|
|
2025
Q1 | $141K | Sell |
119,400
-134,000
| -53% | -$206K | ﹤0.01% | 10968 |
|
|
2024
Q4 | $464K | Buy |
253,400
+155,300
| +158% | +$303K | ﹤0.01% | 8727 |
|
|
2024
Q3 | $167K | Sell |
98,100
-49,600
| -34% | -$81.5K | ﹤0.01% | 10422 |
|
|
2024
Q2 | $202K | Buy |
147,700
+42,400
| +40% | +$85.6K | ﹤0.01% | 9918 |
|
|
2024
Q1 | $395K | Sell |
105,300
-40,500
| -28% | -$237K | ﹤0.01% | 8885 |
|
|
2023
Q4 | $1.43M | Sell |
145,800
-15,000
| -9% | -$123K | ﹤0.01% | 5980 |
|
|
2023
Q3 | $1.34M | Sell |
160,800
-69,900
| -30% | -$799K | ﹤0.01% | 5982 |
|
|
2023
Q2 | $3.07M | Sell |
230,700
-126,800
| -35% | -$1.54M | ﹤0.01% | 4430 |
|
|
2023
Q1 | $4.14M | Buy |
357,500
+96,200
| +37% | +$956K | ﹤0.01% | 4111 |
|
|
2022
Q4 | $2.14M | Buy |
261,300
+196,000
| +300% | +$1.69M | ﹤0.01% | 5348 |
|
|
2022
Q3 | $379K | Sell |
65,300
-900
| -1% | -$5.16K | ﹤0.01% | 9062 |
|
|
2022
Q2 | $293K | Sell |
66,200
-35,800
| -35% | -$218K | ﹤0.01% | 9854 |
|
|
2022
Q1 | $928K | Buy |
102,000
+14,800
| +17% | +$170K | ﹤0.01% | 7879 |
|
|
2021
Q4 | $1.78M | Buy |
87,200
+1,100
| +1% | +$26.5K | ﹤0.01% | 6508 |
|
|
2021
Q3 | $2.2M | Sell |
86,100
-73,700
| -46% | -$2.18M | ﹤0.01% | 6111 |
|
|
2021
Q2 | $5.59M | Sell |
159,800
-158,100
| -50% | -$4.6M | ﹤0.01% | 4199 |
|
|
2021
Q1 | $10.6M | Buy |
317,900
+52,600
| +20% | +$1.84M | ﹤0.01% | 2883 |
|
|
2020
Q4 | $6.88M | Buy |
265,300
+194,500
| +275% | +$3.31M | ﹤0.01% | 3144 |
|
|
2020
Q3 | $699K | Buy |
+70,800
| New | +$408K | ﹤0.01% | 6691 |
|
|
2020
Q2 | – | Sell |
-15,500
| Closed | -$47K | – | 10307 |
|
|
2020
Q1 | $47K | Buy |
+15,500
| New | +$63.5K | ﹤0.01% | 9058 |
|
|
2018
Q4 | – | Sell |
-12,400
| Closed | -$67K | – | 9593 |
|
|
2018
Q3 | $67K | Sell |
12,400
-5,500
| -31% | -$23.6K | ﹤0.01% | 8728 |
|
|
2018
Q2 | $64K | Buy |
+17,900
| New | +$49.7K | ﹤0.01% | 8387 |
|
|
2017
Q1 | – | Sell |
-13,500
| Closed | -$51K | – | 7874 |
|
|
2016
Q4 | $51K | Sell |
13,500
-6,600
| -33% | -$48K | ﹤0.01% | 6866 |
|
|
2016
Q3 | $180K | Buy |
20,100
+9,100
| +83% | +$76.1K | ﹤0.01% | 6369 |
|
|
2016
Q2 | $77K | Sell |
11,000
-3,500
| -24% | -$32K | ﹤0.01% | 6294 |
|
|
2016
Q1 | $123K | Sell |
14,500
-23,400
| -62% | -$230K | ﹤0.01% | 5930 |
|
|
2015
Q4 | $498K | Buy |
37,900
+30,800
| +434% | +$276K | ﹤0.01% | 4477 |
|
|
2015
Q3 | $26K | Sell |
7,100
-400
| -5% | -$1.96K | ﹤0.01% | 8012 |
|
|
2015
Q2 | $43K | Buy |
+7,500
| New | +$43.4K | ﹤0.01% | 7759 |
|
|
2015
Q1 | – | Sell |
-3,400
| Closed | -$27K | – | 8757 |
|
|
2014
Q4 | $27K | Sell |
3,400
-700
| -17% | -$4.48K | ﹤0.01% | 7603 |
|
|
2014
Q3 | $20K | Sell |
4,100
-600
| -13% | -$3.14K | ﹤0.01% | 7418 |
|
|
2014
Q2 | $29K | Buy |
+4,700
| New | +$23.5K | ﹤0.01% | 7094 |
|
Other funds holding PACB
AIM
VCM
NAMA
Citadel Advisors's PACB Position: Q1 2026 in Review
Citadel Advisors reduced its Pacific Biosciences (PACB) stake by 50% in Q1 2026, selling an estimated $2.84M and leaving 1,576,051 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #5984.
Citadel Advisors first reported a position in PACB in Q4 2013 and has held it in 46 quarters since. The position peaked at $58.5M in Q1 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.
- Citadel Advisors held 1,576,051 shares of Pacific Biosciences worth $2.08M as of Q1 2026.
- Citadel Advisors sold 1,590,190 Pacific Biosciences shares in Q1 2026, an estimated $2.84M.
- Pacific Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5984 holding.
- Citadel Advisors first reported a position in Pacific Biosciences in Q4 2013 and has held it in 46 quarters since.
- Citadel Advisors's Pacific Biosciences position peaked at $58.5M in Q1 2023.
- 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.